Plain-English translation of NCT06458972 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study of a medication called telitacicept that was recently approved to treat systemic lupus erythematosus (SLE)—a serious autoimmune disease that affects many parts of the body. Researchers want to understand how well this medication works and how safe it is when patients use it in their regular medical care, not just in controlled research settings.
While this medication has been approved by regulators, doctors and researchers need more information about how it performs in real patients with different backgrounds and health situations. This study will help them understand which patients benefit most and what side effects to watch for.
Researchers will review your medical records and treatment history to see how you're responding to the medication. You will likely have regular clinic visits as part of your normal lupus care, where doctors will monitor your symptoms, do blood tests, and check for any side effects. The study is looking back at real patient data rather than asking you to do anything extra—it's designed to fit into your existing medical routine.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China
Jingzhou Central Hospital, Wuhan Central Hospital
Enrollment target
~139 participants
Started
January 2024
Primary completion
December 2024
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dong Lingli, MD
Tongji Hospital